Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Mok, Tony
Wu, Yi-Long
Watson, Patricia A.
Zhang, Jin
Rangwala, Reshma A.
Lopes, Gilberto
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Soc Clin Oncol, Guangzhou, Guangdong, Peoples R China
[3] IASLC, Guangzhou, Guangdong, Peoples R China
[4] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[5] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[7] Merck & Co Inc, Kenilworth, NJ USA
[8] Ctr Paulista Oncol & HCor Onco, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8105
引用
收藏
页数：1
相关论文
共 50 条
  • [1] KEYNOTE-042: PHASE 3 STUDY OF PEMBROLIZUMAB (MK-3475) VERSUS PLATINUM DOUBLET CHEMOTHERAPY AS FIRST-LINE THERAPY FOR PD-L1-POSITIVE NON-SMALL CELL LUNG CANCER
    Lopes, Gilberto
    Watson, Patricia A.
    Zhang, Jin
    Rangwala, Reshma
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S192 - S192
  • [2] Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study
    Mok, T.
    Wu, Y. -L.
    Sadowski, S.
    Zhang, J.
    Rangwala, R.
    de Lima Lopes, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [3] Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042
    Mok, T.
    Wu, Y. -L.
    Sadowski, S.
    Zhang, J.
    Rangwala, R.
    Kush, D.
    de Lima Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S142 - S142
  • [4] Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001
    Soria, J. C.
    Flotten, O.
    Horn, L.
    Felip, E.
    Gandhi, L.
    Hui, R.
    Hellmann, M.
    Leighl, N.
    Zhang, J.
    Kondic, A.
    Rangwala, R.
    Lubiniecki, G. M.
    Garon, E. B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S726 - S727
  • [5] Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
    Mok, T. S. K.
    Lopes, G.
    Cho, B. C.
    Kowalski, D. M.
    Kasahara, K.
    Wu, Y. -l.
    de Castro Jr, G.
    Turna, H. Z.
    Cristescu, R.
    Aurora-Garg, D.
    Loboda, A.
    Lunceford, J.
    Kobie, J.
    Ayers, M.
    Pietanza, M. C.
    Piperdi, B.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2023, 34 (04) : 377 - 388
  • [6] KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy
    Herbst, R. S.
    Kim, D-W.
    Felip, E.
    Perez-Gracia, J. L.
    Garon, E. B.
    Han, J-Y.
    Molina, J.
    Kim, J-H.
    Gervais, R.
    Ahn, M-J.
    Majem, M.
    Fidler, M. J.
    De Castro, G., Jr.
    Garrido, M.
    Lubiniecki, G. M.
    Shentu, Y.
    Im, E.
    Baas, P.
    ANNALS OF ONCOLOGY, 2015, 26 : 162 - 162
  • [7] Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC
    Mok, T. S. K.
    Wu, Y-L.
    Kudaba, I.
    Kowalski, D. M.
    Cho, B. C.
    Turna, H. Z.
    de Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K. K.
    Bondarenko, I.
    Kubota, K.
    Caglevic, C.
    Karaszewska, B.
    Dang, T.
    Yin, L.
    Penrod, J.
    Lopes, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
  • [8] Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study
    Wu, Yi-Long
    Zhang, Li
    Fan, Yun
    Zhou, JianYing
    Zhang, Li
    Zhou, Qing
    Li, Wei
    Hu, ChengPing
    Chen, GongYan
    Zhang, Xin
    Zhou, CaiCun
    Dang, Thao
    Sadowski, Sara
    Kush, Debra A.
    Zhou, Yu
    Li, Ben
    Mok, Tony
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (09) : 2313 - 2320
  • [9] Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
    Papadimitrakopoulou, Vassiliki
    Patnaik, Amita
    Borghaei, Hossein
    Stevenson, James
    Gandhi, Leena
    Gubens, Matthew A.
    Yang, James Chih-Hsin
    Sequist, Lecia V.
    Ge, Joy Yang
    Bourque, Jennifer
    Bachman, Robert D.
    Im, Ellie
    Gadgeel, Shirish M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
    Sugisaka, J.
    Sugawara, S.
    Toi, Y.
    Ogasawara, T.
    Aso, M.
    Tsurumi, K.
    Ono, K.
    Shimizu, H.
    Domeki, Y.
    Aiba, T.
    Kawana, S.
    Saito, R.
    Terayama, K.
    Kawashima, Y.
    Nakamura, A.
    Yamanda, S.
    Kimura, Y.
    Honda, Y.
    ANNALS OF ONCOLOGY, 2019, 30
12345